Kura Oncology, Inc. annual report, FY2023

Kura Oncology, Inc. Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone quarterly filing. Kura is a clinical-stage biopharmaceutical company focused on precision oncology and has no approved products or historical product revenue.

Business Context and Pipeline

Ziftomenib: Lead menin-KMT2A inhibitor for genetically defined acute leukemias, particularly NPM1-mutant and KMT2A-rearranged AML. The KOMET-001 Phase 2 registration-directed study targets 85 patients, with enrollment expected to be completed by mid-2024.
Tipifarnib: Farnesyl transferase inhibitor. Kura discontinued development as monotherapy despite activity in HRAS-mutant head and neck cancer, but continues the KURRENT-HN combination study with Novartis’s alpelisib.
KO-2806: Next-generation farnesyl transferase inhibitor in the Phase 1 FIT-001 study as monotherapy and in planned combinations with cabozantinib and adagrasib.
Kura owns global commercial rights to its programs and relies on third parties for clinical research, manufacturing, companion diagnostics and certain combination therapies.

Financial and Operating Metrics

Metric	2023	2022	Change
Revenue	No product revenue	No product revenue	No change
Research and development expense	$115.2 million	$92.8 million	+$22.4 million
General and administrative expense	$50.6 million	$47.1 million	+$3.5 million
Total operating expenses	$165.8 million	$139.9 million	+$25.9 million
Other income, net	$13.2 million	$4.0 million	+$9.1 million
Net loss	$152.6 million	$135.8 million	Loss increased $16.8 million
Basic and diluted net loss per share	$2.08	$2.03	Loss per share increased
Net cash used in operating activities	$124.8 million	$110.1 million	Use increased $14.8 million

Research and development spending increased primarily because of higher ziftomenib registration-directed and combination-trial costs, higher KO-2806 Phase 1 costs, and increased discovery activities. Tipifarnib spending declined following closure of its registration-directed monotherapy trial.
Other income benefited from higher interest income on investments. Interest expense increased to $1.5 million from $0.2 million.
Cash, cash equivalents and short-term investments totaled $424.0 million at December 31, 2023, including $37.3 million of cash and cash equivalents and $386.6 million of short-term investments.
Total assets were $448.9 million, total liabilities were $51.7 million, and stockholders’ equity was $397.3 million at year-end.
Accumulated deficit was $721.4 million. No income tax benefit was recorded because deferred tax assets were fully offset by a valuation allowance.

Debt, Liquidity and Capital Resources

Long-term debt had a principal balance of $10.0 million and a carrying value of $9.3 million at December 31, 2023. The term loan bears interest at 10.90% as of year-end and matures in November 2027.
The term loan facility permits additional borrowing of up to $35.0 million through March 15, 2024, a potential additional $40.0 million tranche subject to conditions, and a final $25.0 million tranche subject to lender approval.
The facility includes restrictive covenants, a minimum cash covenant beginning June 1, 2024, collateral over substantially all assets other than intellectual property, and an end-of-term fee of at least approximately $1.5 million.
Contractual obligations disclosed at year-end totaled $25.9 million, including $11.4 million of operating lease payments, $10.0 million of debt principal and $4.5 million of estimated debt interest.
On January 26, 2024, Kura completed a private placement of common stock and pre-funded warrants for approximately $150.0 million of gross proceeds before offering expenses. Management stated that year-end liquidity together with the private-placement proceeds is expected to fund operating expenses into 2027, based on current plans.
Kura also maintains a $150.0 million at-the-market facility but had not sold shares under it as of the filing date.

Material Changes Versus the Prior Period

Net loss increased 12.4% to $152.6 million, while operating expenses increased 18.5% to $165.8 million.
Research and development expense increased 24.2%, led by ziftomenib and KO-2806. Tipifarnib-related expense declined after discontinuation of the monotherapy program.
Operating cash burn increased to $124.8 million from $110.1 million.
Liquidity remained broadly stable in total because short-term investments were approximately $386.6 million in both years, although cash and cash equivalents declined from $51.8 million to $37.3 million.
Shares outstanding increased to 74.4 million at December 31, 2023 from 68.3 million at December 31, 2022, primarily reflecting the June 2023 financing and equity-plan activity. The January 2024 financing added further potential dilution through common shares and pre-funded warrants.

Guidance, Outlook, Risks and Unusual Items

Management expects continued increases in research and development and general and administrative expenses as clinical development expands.
Expected 2024 milestones include completion of KOMET-001 Phase 2 enrollment by mid-year, determination of combination recommended doses for ziftomenib with venetoclax/azacitidine and 7+3 by mid-year, initiation of additional KO-2806 combination cohorts, and continued KURRENT-HN dose escalation with an optimal biologically active dose expected by the end of 2024.
Ziftomenib’s principal clinical risk includes differentiation syndrome. In KOMET-001, 15% of patients experienced Grade 1 or 2 events and 5% experienced a Grade 3 event. A prior Grade 5 event led to a partial clinical hold in 2021; the hold was lifted in January 2022.
Kura remains dependent on regulatory approval of ziftomenib, particularly in relapsed or refractory NPM1-mutant AML. Clinical results may not support approval, and competing menin inhibitor revumenib could reach the market earlier in a related indication.
KO-2806 is being tested in humans for the first time, so its safety profile remains uncertain. Clinical trials also depend on supplies from third parties, including alpelisib from Novartis and adagrasib from Mirati.
Companion diagnostics may be required for approval and could create additional development, regulatory, reimbursement and commercialization risks.
The company recognized a $2.8 million employee retention credit receivable in 2023, recorded as a reduction of personnel costs. The filing also identifies clinical-trial accruals as a critical audit matter; accrued clinical-trial research and development expenses were $7.7 million at year-end.
Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls as of December 31, 2023.

Most Important Facts for Investors to Verify

Current enrollment, data quality, safety profile and regulatory interaction for the KOMET-001 Phase 2 ziftomenib study.
Whether ziftomenib can demonstrate sufficient efficacy and safety for an NDA, including the impact of differentiation syndrome and resistance mutations.
Cash burn, investment maturities, debt covenants and the duration of liquidity under updated clinical-development assumptions.
The final net proceeds, share count and dilution from the January 2024 private placement and any subsequent ATM sales or warrant exercises.
Progress and clinical signal from ziftomenib combination studies, KURRENT-HN and the KO-2806 FIT-001 program.
Availability and regulatory status of required companion diagnostics and third-party combination drugs.
Patent scope and remaining protection for ziftomenib, tipifarnib and KO-2806, including licensed-rights obligations and potential milestone or royalty payments.